Nonsteroidal anti-inflammatory drugs: a modern understanding of the mechanisms of damage to the digestive tract, the shortcomings of pathogenetic drugs and prospects for biological therapy of NSAID-induced esophagogastroenterocolonopathy
DOI:
https://doi.org/10.22141/2308-2097.54.4.2020.216714Keywords:
nonsteroidal anti-inflammatory drugs, ulcerogenicity, esophagogastroenterocolonopathy, cryopreserved placental extractAbstract
Background. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used daily by more than 30 million people, and their arsenal includes more than 80 drugs and about 1,000 dosage forms based on them. They are widely used in many areas of medicine and are one of the most clinically significant groups of drugs. However, the use of NSAIDs can often cause side effects, the most common of which are damage to the gastrointestinal tract. Objective: to characterize the current understanding of the mechanisms of damage to the digestive tract by nonsteroidal anti-inflammatory drugs, to assess the shortcomings of existing pathogenetic drugs and prospects for biological therapy of NSAID-induced esophagogastroenterocolonopathy with cryopreserved human placental extract. Materials and methods. The analysis was performed of the works published in 2010–2020, which covered information on the epidemiology, pathogenesis, diagnosis and treatment of lesions of the esophagus and gastrointestinal tract induced by nonsteroidal anti-inflammatory drugs, as well as the biological properties of cryopreserved human placental extract as biological therapy. Results. Treatment of NSAID-induced esophagogastroenterocolonopathy is usually aimed at acid-suppressive therapy (proton pump inhibitors, H2-histamine blockers, etc.), the use of gastrocytoprotectors (de-nol, sucralfate, etc.) and drugs that restore the content of prostaglandins in the mucous membrane (misoprostol, rebamipide, etc.). However, all these groups of drugs do not sufficiently satisfy clinicians, as they are aimed primarily at treating NSAID gastropathy and have their own side effects. A new promising area for improving the safety of NSAIDs today is the use of biological therapies, the sources of which are microorganisms, organs and tissues of plant or animal origin, cells or fluids (including blood and plasma) of human or animal origin and biotechnological cell structures. Conclusions. The use of nonsteroidal anti-inflammatory drugs is significantly limited by their side effects, the most common of which are disorders of the gastrointestinal tract. Cryopreserved human placental extract is a promising biological therapy for ulcerogenic lesions of the gastrointestinal tract induced by nonsteroidal anti-inflammatory drugs.References
Podpletniaia EA, Mamchur VI. Mechanisms of gastroduodenotoxicity of non-steroidal anti-inflammatory drugs. Journal of the National Academy of Medical Sciences of Ukraine. 2005;(1):47-62. (in Russian).
Ul'ianina LR, Il'in DA, Karimova D.R. Experimental evaluation of gastroprotective activity of L-methionine and lithium L-methioninate on the model of indometacin gastric ulcer. In: Proceeding of the 88th All-Russian Scientific and Practical Conference of Students and Young Scientists dedicated to the 200th anniversary of the Kazan State Medical University. 2014, March 26-27; Kazan, Russian federation. Kazan; 2014. 175 p. (in Russian).
Nasadyuk SM. Biochemical characteristics and approaches to the use of placental extracts in medical practice. Z turbotoju pro zhinku. 2013;(43):54-56. (in Ukrainian).
Downloads
Published
2020-09-01
Issue
Section
Reviews and Lections
License
Copyright (c) 2020 GASTROENTEROLOGY
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
